A Phase 1 interventional study of MEDI0618 and Placebo in Chronic Pain, sponsored by AstraZeneca. Completed at 1 site in Germany. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-10-16.
Sponsored by AstraZeneca · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 70 studies in Chronic Pain with a site in Germany — 11 open to participants now, 14 under way, 8 of them phase 3. Chronic Pain · Germany.
Among the 70 studies in Chronic Pain with a site in Germany, this one is the 33rd largest by enrollment of the 50 interventional ones that give a count, is one of 5 that started in 2019, is one of 4 in phase 1, and was the 47th registered.
3,228 studies on the registry are indexed under Chronic Pain; 729 are open to participants now.
Browse Chronic Pain studies →11 of the 70 studies in Chronic Pain with a site in Germany are open now. Recruiting first, the newest first:
Apurano Pharmaceuticals GmbH · Sites in Germany
Ages 18+
Apurano Pharmaceuticals GmbH · Sites in Germany
Ages 18+
Apurano Pharmaceuticals GmbH · Sites in Germany
Ages 18+
Apurano Pharmaceuticals GmbH · Sites in Germany
Ages 18+
Apurano Pharmaceuticals GmbH · Sites in Germany
Ages 18+
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 486 Chronic Pain studies recruiting now, 239 (49%) set no upper age limit and 173 (36%) stop at 75 or younger; 43 take children under 18; 64 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
70 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 6 · Phase 3 17 · Phase 4 2
First in 2003; this study’s year is marked. 5 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 64 is close to the median of 60 across 2,388 interventional studies indexed under Chronic Pain.
Median enrollment 91 across the 50 interventional studies, 167 across the 20 observational. Of the 54 that completed or were terminated, 21 (39%) have results posted.
This tab as a report to print or save as PDF → With an account.
45 of 70 have an industry lead sponsor. The 10 most frequent:
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
AstraZeneca has 6 studies filed under Chronic Pain — fewer than ten, so there is no comparison to draw.
1 of the studies in Chronic Pain with a site in Germany that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06784141Prof. Dr. Julia GlombiewskiNetwork-Based vs. Standardized Cognitive Behavioral Therapy in Chronic Primary Pain | 2027-04 |
Add it to your calendar (.ics) → With an account.
Among the 70 studies in Chronic Pain with a site in Germany, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a randomised, placebo-controlled study of the safety and tolerability of single doses of MEDI0618 in healthy volunteer subjects.
This is a randomised, double-blind, placebo-controlled study of the safety, tolerability and pharmacokinetics of single ascending doses of MEDI0618 in healthy male and female volunteers.
This study will include 9 planned cohorts; 8 cohorts will receive single ascending doses of MEDI0618 or placebo by intravenous administration, 1 cohort will receive MEDI0618 or placebo by subcutaneous administration.All subjects will undergo scheduled safety, tolerability, pharmacokinetic and immunogenicity assessments while in the clinical unit and as outpatients to the end of the follow-up period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
MEDI0618 or placebo
Drug: MEDI0618 · Drug: Placebo
MEDI0618 or placebo
Drug: MEDI0618 · Drug: Placebo
MEDI0618 or placebo
Drug: MEDI0618 · Drug: Placebo
MEDI0618 or placebo
Drug: MEDI0618 · Drug: Placebo
MEDI0618 or placebo
Drug: MEDI0618 · Drug: Placebo
MEDI0618 or placebo
Drug: MEDI0618 · Drug: Placebo
MEDI0618 or placebo
Drug: MEDI0618 · Drug: Placebo
MEDI0618 or placebo
Drug: MEDI0618 · Drug: Placebo
MEDI0618 or placebo
Drug: MEDI0618 · Drug: Placebo
MEDI0618 A novel human immunoglobulin antibody
Placebo
Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]
Adverse Events
Time frame: Up to 85 days
Incidence of Treatment-Emergent Serious Adverse Events
Serious Adverse Events
Time frame: Up to 85 days
Vital Signs
Heart Rate in beats per minute
Time frame: Up to 85 days
Vital Signs
Blood pressure in mm Hg
Time frame: Up to 85 days
Body Weight
Weight in kg
Time frame: Up to 85 days
Height
Height in meters Height and weight will be combined to report BMI in kg/m\^2
Time frame: Up to 85 days
Clinical Chemistry
Measurement of Albumin, Protein, Aspartate transaminase, Alanine transaminase, Alkaline phosphatase, Bilirubin, Calcium, Creatine phosphokinase, C-reactive protein, Glucose, Blood urea nitrogen, Phosphate, Potassium, Sodium, Chloride and Bicarbonate
Time frame: Up to 85 days
Haematology
Measurement of Haemoglobin, Haematocrit, Leukocyte count, Platelet count, Erythrocyte count, Reticulocyte count, Mean corpuscular haemoglobin
Time frame: Up to 85 days
Thyroid Function
Measurement of Thyroid-stimulating hormone and free thyroxine
Time frame: Up to 85 days
Renal Function
Measurement of Glomerular filtration rate
Time frame: Up to 85 days
Urinalysis
Measurement of Haemoglobin, Leukocytes, Glucose, Protein and Creatinine
Time frame: Up to 85 days
12-Lead Electrocardiogram
Measurement of Heart rate; PR, QRS, RR, QT and QTc intervals from digital recordings
Time frame: Up to 85 days
Physical Examination
General physical examination
Time frame: Up to 85 days
Peak plasma concentration (Cmax)
Peak concentration of MEDI0618 in plasma
Time frame: Up to 85 days
Time to maximum concentration (tmax)
Time to maximum concentration of MEDI0618 in plasma
Time frame: Up to 85 days
Area under the concentration versus time curve (AUC)
Calculated area under the concentration versus time curve for MEDI0618
Time frame: Up to 85 days
Terminal half-life
Time required for the plasma concentration of MEDI0618 to decrease by 50%
Time frame: Up to 85 days
Bioavailability
The fraction of MEDI0618 administered that is available to the systemic circulation
Time frame: Up to 85 days
Anti-drug antibody incidence and titres
Anti-drug (MEDI0618) antibody incidence and titres
Time frame: Up to 85 days
Plan to share: Yes — Anonymised individual patient-level data will be shared.
Time frame: After CSR sign-off.
Access criteria: Qualified researchers.
Ran from Nov 2019 to primary completion in Feb 2022, 26 months.
Of 27 industry-sponsored phase 1 interventional studies under Chronic Pain, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 12. This study's 26 months is above that.
Counting every sponsor, half of 60 studies reached it within 12 months; a quarter within 6 and three quarters within 56.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: MEDI0618